References

nogr

Экспериментальная и клиническая гастроэнтерология

Experimental and Clinical Gastroenterology

1682-8658

«Global Media Technologies»

10.31146/1682-8658-ecg-218-10-175-181

nogr-2562

Research Article

ГЕПАТОЛОГИЯ

HEPATOLOGY

Пути преодоления трудностей в диагносткие неалкогольной жировой болезни печени

Ways to overcome difficulties in diagnosing non-alcoholic fatty liver disease

Аляви

А. Л.

Alyavi

A. L.

noemail@neicon.ru

Собирова

Г. Н.

Sobirova

G. N.

noemail@neicon.ru

Абдуллаев

А. О.

Abdullaev

A. O.

noemail@neicon.ru

Шадманова

Д. А.

Shadmanova

D. A.

noemail@neicon.ru

ГУ «Республиканского специализированного научно-практического медицинского центра терапии и медицинской реабилитации» (РСНПМЦТ и МР) Ташкентская медицинская академия (ТМА)РоссияState Institution “Republican Specialized Scientific and Practical Medical Center for Therapy and Medical Rehabilitation” (RSNPMCT and MR) Tashkent Medical Academy (TMA)Russian Federation

2023

15032024

010175181

2024

Аляви А.Л., Собирова Г.Н., Абдуллаев А.О., Шадманова Д.А.

Alyavi A.L., Sobirova G.N., Abdullaev A.O., Shadmanova D.A.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.nogr.org/jour/article/view/2562

Цель исследования - в рамках метаанализа научных данных оценить состояние и возможности современных видов диагностики неалкогольной жировой болезни печени. Материалы и методы. Поиск литературы проводили в электронных базах данных Cochrane Library, PubMed.gov, Elsevier.com, Google Scholar. Анализ полученных данных был сосредоточен на работах, опубликованных в период с 2010 по 2023 год (погрешность, в виде более поздних исследований, использовали в единичных случаях, когда речь шла о фундаментальных наукометрических данных). Результаты. После процедур ревизии 693 научных работ на предмет дублирования и не соответствия, было отобрано 38 источников. Выводы. В ходе анализа научных данных было выявлено, что несмотря на понимание патогенетических причин возникновения неалкогольной жировой болезни печени и сложность данного заболевания, биопсия печени по-прежнему остается золотым стандартом оценки здоровья печени. В связи с этим есть потребность внедрения доступных невизуализирующих инструментов и точных биомаркеров, с помощью которых можно будет не только осуществлять адекватную постановку диагноза, но и в рамках клинических испытаний анализировать новые методы лечения НЖБП.

The purpose of the study is to evaluate the status and capabilities of modern types of diagnostics of non-alcoholic fatty liver disease as part of a meta-analysis of scientific data. Materials and methods. The literature search was carried out in electronic databases Cochrane Library, PubMed.gov, Elsevier.com, Google Scholar. The analysis of the data obtained was focused on works published between 2010 and 2023 (the bias in the form of later studies was used in isolated cases when it came to fundamental scientometric data). Results. After reviewing 693 scientific papers for duplication and inconsistency, 38 sources were selected. Conclusions. The analysis of scientific data revealed that despite the understanding of the pathogenetic causes of non-alcoholic fatty liver disease and the complexity of this disease, liver biopsy still remains the gold standard for assessing liver health. In this regard, there is a need to introduce accessible non-imaging tools and accurate biomarkers, with the help of which it will be possible not only to make an adequate diagnosis, but also to analyze new treatments for NAFLD in clinical trials.

неалкогольная жировая болезнь печени (НЖБП)неалкогольный стеатогепатит (НСГ)диагностика НЖБП

non-alcoholic fatty liver disease (NAFLD)non-alcoholic steatohepatitis (NSH)diagnosis ofNAFLD

References1

Jennison E., Patel J., Scorletti E., Byrne C. D. Diagnosis and management of non-alcoholic fatty liver disease. Postgrad Med J. 2019 Jun;95(1124):314-322. doi: 10.1136/postgradmedj-2018-136316.

Volkova N. I., Porksheyan M. I. Nonalcoholic fatty liver disease: What do we know and what will we have to learn? Terapevticheskii Arkhiv. 2017;89(2):91-98. (In Russ.) doi: 10.17116/terarkh201789291-98.

Younossi Z. M., Stepanova M., Younossi Y., Golabi P., Mishra A., Rafiq N., Henry L. Epidemiology of chronic liver diseases in the USA in the past three decades. Gut. 2020 Mar;69(3):564-568. doi: 10.1136/gutjnl-2019-318813.

Younes R., Bugianesi E. NASH in Lean Individuals. Semin Liver Dis. 2019 Feb;39(1):86-95. doi: 10.1055/s-0038-1677517.

Alonso C., Fernández-Ramos D., Varela-Rey M. et al. Metabolomic Identification of Subtypes of Nonalcoholic Steatohepatitis. Gastroenterology. 2017 May;152(6):1449-1461.e7. doi: 10.1053/j.gastro.2017.01.015.

Younossi Z., Anstee Q. M., Marietti M., Hardy T., Henry L., Eslam M., George J., Bugianesi E. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018 Jan;15(1):11-20. doi: 10.1038/nrgastro.2017.109.

Cai J., Zhang X. J., Li H. Progress and challenges in the prevention and control of nonalcoholic fatty liver disease. Med Res Rev. 2019 Jan;39(1):328-348. doi: 10.1002/med.21515.

Friedman S. L., Neuschwander-Tetri B. A., Rinella M., Sanyal A. J. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018 Jul;24(7):908-922. doi: 10.1038/s41591-018-0104-9.

Cotter T. G., Rinella M. Nonalcoholic Fatty Liver Disease 2020: The State of the Disease. Gastroenterology. 2020 May;158(7):1851-1864. doi: 10.1053/j.gastro.2020.01.052.

Prati D., Taioli E., Zanella A., Della Torre E. et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med. 2002 Jul 2;137(1):1-10. doi: 10.7326/0003-4819-137-1-200207020-00006.

López-Suárez A., Guerrero J. M., Elvira-González J., Beltrán-Robles M., Cañas-Hormigo F., Bascuñana-Quirell A. Nonalcoholic fatty liver disease is associated with blood pressure in hypertensive and nonhypertensive individuals from the general population with normal levels of alanine aminotransferase. Eur J Gastroenterol Hepatol. 2011 Nov;23(11):1011-7. doi: 10.1097/MEG.0b013e32834b8d52.

Koehler EM, Schouten JN, Hansen BE, Hofman A, Stricker BH, Janssen HL. External validation of the fatty liver index for identifying nonalcoholic fatty liver disease in a population-based study. Clin Gastroenterol Hepatol. 2013 Sep;11(9):1201-4. doi: 10.1016/j.cgh.2012.12.031.

Kotronen A, Peltonen M, Hakkarainen A, Sevastianova K, Bergholm R, Johansson LM, Lundbom N, Rissanen A, Ridderstråle M, Groop L, Orho-Melander M, Yki-Järvinen H. Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology. 2009 Sep;137(3):865-72. doi: 10.1053/j.gastro.2009.06.005.

Hernaez R, Lazo M, Bonekamp S, Kamel I, Brancati FL, Guallar E, Clark JM. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology. 2011 Sep 2;54(3):1082-1090. doi: 10.1002/hep.24452.

Ballestri S, Nascimbeni F, Baldelli E, Marrazzo A, Romagnoli D, Targher G, Lonardo A. Ultrasonographic fatty liver indicator detects mild steatosis and correlates with metabolic/histological parameters in various liver diseases. Metabolism. 2017 Jul;72:57-65. doi: 10.1016/j.metabol.2017.04.003.

Strauss S, Gavish E, Gottlieb P, Katsnelson L.Interobserver and intraobserver variability in the sonographic assessment of fatty liver. AJR Am J Roentgenol. 2007 Dec;189(6): W320-3. doi: 10.2214/AJR.07.2123.

Saverymuttu SH, Joseph AE, Maxwell JD. Ultrasound scanning in the detection of hepatic fibrosis and steatosis. Br Med J (Clin Res Ed). 1986 Jan 4;292(6512):13-5. doi: 10.1136/bmj.292.6512.13.

de Lédinghen V, Vergniol J, Foucher J, Merrouche W, le Bail B. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography. Liver Int. 2012 Jul;32(6):911-8. doi: 10.1111/j.1478-3231.2012.02820.x.

Zhang B, Ding F, Chen T, Xia LH, Qian J, Lv GY. Ultrasound hepatic/renal ratio and hepatic attenuation rate for quantifying liver fat content. World J Gastroenterol. 2014 Dec 21;20(47):17985-92. doi: 10.3748/wjg.v20.i47.17985.

Noureddin M, Lam J, Peterson MR, Middleton M, Hamilton G, Le TA, Bettencourt R, Changchien C, Brenner DA, Sirlin C, Loomba R. Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials. Hepatology. 2013 Dec;58(6):1930-40. doi: 10.1002/hep.26455.

Georgoff P, Thomasson D, Louie A, Fleischman E, Dutcher L, Mani H, Kottilil S, Morse C, Dodd L, Kleiner D, Hadigan C. Hydrogen-1 MR spectroscopy for measurement and diagnosis of hepatic steatosis. AJR Am J Roentgenol. 2012 Jul;199(1):2-7. doi: 10.2214/AJR.11.7384.

Idilman IS, Aniktar H, Idilman R, Kabacam G, Savas B, Elhan A, Celik A, Bahar K, Karcaaltincaba M. Hepatic steatosis: quantification by proton density fat fraction with MR imaging versus liver biopsy. Radiology. 2013 Jun;267(3):767-75. doi: 10.1148/radiol.13121360.

Pavlides M, Banerjee R, Tunnicliffe EM, Kelly C, Collier J, Wang LM, Fleming KA, Cobbold JF, Robson MD, Neubauer S, Barnes E. Multiparametric magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease severity. Liver Int. 2017 Jul;37(7):1065-1073. doi: 10.1111/liv.13284.

Loomba R, Wolfson T, Ang B, Hooker J, Behling C, Peterson M, Valasek M, Lin G, Brenner D, Gamst A, Ehman R, Sirlin C. Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: a prospective study. Hepatology. 2014 Dec;60(6):1920-8. doi: 10.1002/hep.27362.

Chamoun Z, Vacca F, Parton RG, Gruenberg J. PNPLA3/adiponutrin functions in lipid droplet formation. Biol Cell. 2013 May;105(5):219-233. doi: 10.1111/boc.201200036.

Lee SS, Byoun YS, Jeong SH, Woo BH, Jang ES, Kim JW, Kim HY. Role of the PNPLA3 I148M polymorphism in nonalcoholic fatty liver disease and fibrosis in Korea. Dig Dis Sci. 2014 Dec;59(12):2967-74. doi: 10.1007/s10620-014-3279-z.

Romeo S, Sentinelli F, Dash S, Yeo GS, Savage DB, Leonetti F, Capoccia D, Incani M, Maglio C, Iacovino M, O’Rahilly S, Baroni MG. Morbid obesity exposes the association between PNPLA3 I148M (rs738409) and indices of hepatic injury in individuals of European descent.Int J Obes (Lond). 2010 Jan;34(1):190-4. doi: 10.1038/ijo.2009.216.

Luukkonen PK, Zhou Y, Nidhina Haridas PA, Dwivedi OP, Hyötyläinen T, Ali A, Juuti A, Leivonen M, Tukiainen T, Ahonen L, Scott E, Palmer JM, Arola J, Orho-Melander M, Vikman P, Anstee QM, Olkkonen VM, Orešič M, Groop L, Yki-Järvinen H. Impaired hepatic lipid synthesis from polyunsaturated fatty acids in TM6SF2 E167K variant carriers with NAFLD. J Hepatol. 2017 Jul;67(1):128-136. doi: 10.1016/j.jhep.2017.02.014.

Kim DS, Jackson AU, Li YK, Stringham HM, Kuusisto J, Kangas AJ, Soininen P, Ala-Korpela M, Burant CF, Salomaa V, Boehnke M, Laakso M, Speliotes EK. Novel association of TM6SF2 rs58542926 genotype with increased serum tyrosine levels and decreased apoB-100 particles in Finns. J Lipid Res. 2017 Jul;58(7):1471-1481. doi: 10.1194/jlr.P076034.

Valenti L, Alisi A, Nobili V. Unraveling the genetics of fatty liver in obese children: additive effect of P446L GCKR and I148M PNPLA3 polymorphisms. Hepatology. 2012 Mar;55(3):661-3. doi: 10.1002/hep.25617.

Kumari M, Schoiswohl G, Chitraju C, Paar M, Cornaciu I, Rangrez AY, et al. Adiponutrin functions as a nutritionally regulated lysophosphatidic Acid acyltransferase. Cell Metab. 2012;15:691-702.

Valenti L, Motta BM, Alisi A, Sartorelli R, Buonaiuto G, Dongiovanni P, Rametta R, Pelusi S, Fargion S, Nobili V. LPIN1 rs13412852 polymorphism in pediatric nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr. 2012 May;54(5):588-93. doi: 10.1097/MPG.0b013e3182442a55.

Fares R, Petta S, Lombardi R, Grimaudo S, Dongiovanni P, Pipitone R, Rametta R, Fracanzani AL, Mozzi E, Craxì A, Fargion S, Sesti G, Valenti L. The UCP2-866 G>A promoter region polymorphism is associated with nonalcoholic steatohepatitis. Liver Int. 2015 May;35(5):1574-80. doi: 10.1111/liv.12707.

Al-Serri A, Anstee QM, Valenti L, Nobili V, Leathart JB, Dongiovanni P, et al. The SOD2 C47T polymorphism influences NAFLD fibrosis severity: evidence from case-control and intra-familial allele association studies. J Hepatol. 2012;56:448-454.

Nassir F. NAFLD: Mechanisms, Treatments, and Biomarkers. Biomolecules. 2022 Jun 13;12(6):824. doi: 10.3390/biom12060824.

Panni S, Lovering RC, Porras P, Orchard S. Non-coding RNA regulatory networks. Biochim Biophys Acta Gene Regul Mech. 2020 Jun;1863(6):194417. doi: 10.1016/j.bbagrm.2019.194417.

Khalifa O, Errafii K, Al-Akl NS, Arredouani A. Noncoding RNAs in Nonalcoholic Fatty Liver Disease: Potential Diagnosis and Prognosis Biomarkers. Dis Markers. 2020 Aug 27;2020:8822859. doi: 10.1155/2020/8822859.

Qian X, Zong W, Ma L, Yang Z, Chen W, Yan J, Xu J. MM-associated circular RNA downregulates microRNA-19a through methylation to suppress proliferation of pancreatic adenocarcinoma cells. Bioengineered. 2022 Apr;13(4):9294-9300. doi: 10.1080/21655979.2022.2051815.

Fang Z, Dou G, Wang L. MicroRNAs in the Pathogenesis of Nonalcoholic Fatty Liver Disease.Int J Biol Sci. 2021 Apr 29;17(7):1851-1863. doi: 10.7150/ijbs.59588.

Pirola CJ, Fernández Gianotti T, Castaño GO, Mallardi P, San Martino J, Mora Gonzalez Lopez Ledesma M, Flichman D, Mirshahi F, Sanyal AJ, Sookoian S. Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis. Gut. 2015 May;64(5):800-12. doi: 10.1136/gutjnl-2014-306996.

Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA, Boerwinkle E, Cohen JC, Hobbs HH. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008 Dec;40(12):1461-5. doi: 10.1038/ng.257.

The authors declare that there are no conflicts of interest present.